Showa Denko Materials Co., Ltd. and Kidswell Bio Corp. have entered an agreement to enable process development and clinical manufacturing of cell therapy products using the advantage of SHED*2 (Stem cells from Human Exfoliated Deciduous teeth) which is under development by Kidswell Bio. Under the agreement, Minaris Regenerative Medicine Co., Ltd., a subsidiary of Showa Denko Materials, will provide process development services and potential clinical manufacturing of cell therapy products by the end of 2024. Kidswell Bio plans to initiate clinical trials in cooperation with its partner pharmaceutical companies or medical institutions.
